Wegovy and Ozempic are both prescription drugs that are used to treat obesity and help people lose weight. However, there are some differences between the two drugs that are worth noting.

Wegovy, also known as semaglutide, is a GLP-1 receptor agonist that was approved by the FDA in June 2021 [1]. It is administered as a subcutaneous injection once a week and works by mimicking the effects of a hormone called glucagon-like peptide-1 (GLP-1) in the body. GLP-1 is naturally produced in the intestines and helps to regulate blood sugar levels and appetite. By activating GLP-1 receptors in the brain, Wegovy can help reduce hunger and increase feelings of fullness, leading to weight loss [3].

Ozempic, also known as semaglutide, is another GLP-1 receptor agonist that was approved by the FDA in December 2017 [2]. Like Wegovy, it is administered as a subcutaneous injection once a week and works by activating GLP-1 receptors in the brain to reduce appetite and increase feelings of fullness [3].

One key difference between the two drugs is their approved uses. While Wegovy is specifically approved for chronic weight management in adults with a body mass index (BMI) of 27 kg/m² or greater who have at least one weight-related condition, such as type 2 diabetes or high blood pressure [1], Ozempic is approved for both type 2 diabetes and chronic weight management in adults with a BMI of 30 kg/m² or greater or in those with a BMI of 27 kg/m² or greater who have at least one weight-related condition [2].

Another difference between the two drugs is their cost. According to GoodRx [2], as of September 2021, the average retail price for a 4-week supply of Wegovy is around $1,300, while the average retail price for a 4-week supply of Ozempic is around $950. However, these prices may vary depending on factors such as insurance coverage and pharmacy discounts.

In conclusion, Wegovy and Ozempic are both GLP-1 receptor agonists that can help with weight loss, but they have some differences in their approved uses and cost. It is important to talk to a healthcare provider to determine which drug may be right for an individual's specific needs.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/WEGOVY
[2] https://www.goodrx.com/classes/glp-1-agonists/wegovy-vs-ozempic
[3] https://www.uchealth.org/today/wegovy-vs-ozempic-the-truth-about-new-weight-loss-drugs/